Science

Pre-Clinical Portfolio

fig1

Celleron’s preclinical pipeline consists of a series of target enzymes involved in control of epigenesis with key roles in cancer biology. They have been selected using a systems biology approach to increase the likelihood of biochemical synergy when these enter the clinic. Our experience tells us that anticancer drugs are most unlikely to be curative on their own, hence the need to develop rational combination cancer therapy, one of Celleron’s particular strengths.

Clinical products

CXD101

svg
CXD1-2

Celleron’s proprietary drug, CXD101, is a dual mechanism HDAC inhibitor with multiple properties that differentiate it from competing compounds. CXD101 is a novel epigenetic immune-regulator which has the ability to enhance immune recognition of tumour cells. This is particularly important as CXD101 has great potential as a partner in combination with established immune-oncology agents to increase the likelihood of the tumour’s immune recognition and destruction. Its mode of action and chemistry are well characterised and show a slow on/off mechanism and unique chemistry. In preclinical studies CXD101 is active as monotherapy in lung and colon xenograft models. The effect on cell proliferation in tumour cell line models both for Non-Hodgkin’s Lymphoma and for multiple myeloma have been studied. CXD101 has shown clinically important tumour remissions in the Phase I trial.

CXD201

CXD201 is a proprietary topoisomerase inhibitor with multiple points of difference from competing products. CXD201 is derived from the homocamptothecin family, exhibiting a unique chemical composition and improved pharmacological properties.

CXD201 is active in an impressive range of xenograft tumour progression models. CXD201 has already entered a series of Phase I studies, showing clinical activity with a very tolerable side effect profile. CXD201 is orally administered and ready for entry into Phase II clinical trials.

Clinical trials

fig3